R B Walter

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. ncbi Gemcitabine-associated hemolytic-uremic syndrome
    Roland B Walter
    Medical Clinic B and Division of Oncology, Department of Internal Medicine, University Hospital, Zurich, Switzerland
    Am J Kidney Dis 40:E16. 2002
  2. ncbi Life-threatening thrombocytopenia associated with acute Epstein-Barr virus infection in an older adult
    R B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2 373, Seattle, WA 98109 1024, USA
    Ann Hematol 81:672-5. 2002
  3. ncbi The role of CD33 as therapeutic target in acute myeloid leukemia
    Roland B Walter
    Fred Hutchinson Cancer Research Center, Clinical Research Division, 1100 Fairview Ave N, D2 190, Seattle, WA 98109 1024, USA 1 206 667 3599 1 206 667 5255
    Expert Opin Ther Targets 18:715-8. 2014
  4. pmc Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study
    Roland B Walter
    Haematologica 99:54-9. 2014
  5. pmc Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1924, USA
    Blood 122:1813-21. 2013
  6. pmc Height as an explanatory factor for sex differences in human cancer
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Natl Cancer Inst 105:860-8. 2013
  7. pmc Regular recreational physical activity and risk of hematologic malignancies: results from the prospective VITamins And lifestyle (VITAL) study
    R B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Ann Oncol 24:1370-7. 2013
  8. pmc Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 121:2424-31. 2013
  9. pmc Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 119:6198-208. 2012
  10. pmc Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Haematologica 97:739-42. 2012

Detail Information

Publications35

  1. ncbi Gemcitabine-associated hemolytic-uremic syndrome
    Roland B Walter
    Medical Clinic B and Division of Oncology, Department of Internal Medicine, University Hospital, Zurich, Switzerland
    Am J Kidney Dis 40:E16. 2002
    ..Gemcitabine has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported...
  2. ncbi Life-threatening thrombocytopenia associated with acute Epstein-Barr virus infection in an older adult
    R B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2 373, Seattle, WA 98109 1024, USA
    Ann Hematol 81:672-5. 2002
    ..In this report we also briefly summarize the literature on EBV-associated severe thrombocytopenia...
  3. ncbi The role of CD33 as therapeutic target in acute myeloid leukemia
    Roland B Walter
    Fred Hutchinson Cancer Research Center, Clinical Research Division, 1100 Fairview Ave N, D2 190, Seattle, WA 98109 1024, USA 1 206 667 3599 1 206 667 5255
    Expert Opin Ther Targets 18:715-8. 2014
    ....
  4. pmc Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study
    Roland B Walter
    Haematologica 99:54-9. 2014
    ..95 days (range 36-900); P=0.0023). These data indicate that vorinostat/azacitidine/gemtuzumab ozogamicin has activity in this difficult-to-treat acute myeloid leukemia patient subset. (ClinicalTrials.gov: identifier 00895934)...
  5. pmc Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1924, USA
    Blood 122:1813-21. 2013
    ..90 times higher for MRD(pos) patients (P < .001). Together, our findings indicate that the negative impact of pre-HCT MRD is similar for AML in CR1 and CR2 with even minute levels (≤ 0.1%) as being associated with adverse outcome...
  6. pmc Height as an explanatory factor for sex differences in human cancer
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Natl Cancer Inst 105:860-8. 2013
    ..Numerous explanations for this excess risk have been proposed, yet no study has quantified the degree to which height explains the sex difference even though greater height has been associated with increased risk for many cancers...
  7. pmc Regular recreational physical activity and risk of hematologic malignancies: results from the prospective VITamins And lifestyle (VITAL) study
    R B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Ann Oncol 24:1370-7. 2013
    ..Conflicting evidence exists on the relationship between physical activity (PA) and incident hematologic malignancies. Herein, we used a large cohort study to examine this association...
  8. pmc Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 121:2424-31. 2013
    ..In conclusion, in the 2008 WHO classification scheme, FAB subclassification does not provide prognostic information for "AML, NOS" cases if data on NPM1 and CEBPA mutations are available...
  9. pmc Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 119:6198-208. 2012
    ..Herein, we review studies on the nature of stem cells in AML, discuss clinical data on the effectiveness of CD33-directed therapy, and consider the mechanistic basis for success and failure in various AML subsets...
  10. pmc Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Haematologica 97:739-42. 2012
    ..0%); group 2A, 6 of 13 (46.2%); and group 2B, none of 8 (0%). These data indicate that vorinostat+gemtuzumab ozogamicin has activity that is mostly confined to patients with normal karyotype disease. ClinicalTrial.gov: NCT00673153...
  11. pmc Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission
    R B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Leukemia 24:1276-82. 2010
    ..16 (0.52-2.61), P=0.71). These data indicate that URD HCT can provide long-term survival for CR1 AML; outcomes for 10/10 URD HCT, and possibly 9/10 URD HCT, suggest that this modality should be considered in the absence of a suitable MRD...
  12. pmc Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 116:2420-8. 2010
    ..We also suggest strategies for trial design improvement. Although our focus is on the treatment of AML, the principles that we highlight should be broadly applicable to the evaluation of new treatments for a variety of diseases...
  13. pmc Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Clin Oncol 29:1190-7. 2011
    ..Hitherto, little attention has been given to the prognostic impact of pretransplantation minimal residual disease (MRD)...
  14. pmc Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2 190 Seattle, WA 98109 1024, USA
    Haematologica 96:914-7. 2011
    ..08), and incurred lower median daily charges ($3,270 vs. $5,467; P=0.01) than controls. Thus, early discharge of selected patients appears, safe and may reduce cost and resource utilization. (ClinicalTrials.gov Identifier: NCT00844441)...
  15. pmc Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective Vitamins and Lifestyle (VITAL) study
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109 1024, USA
    J Clin Oncol 29:2424-31. 2011
    ..Herein, we used a large prospective cohort study to examine these associations...
  16. pmc Vitamin, mineral, and specialty supplements and risk of hematologic malignancies in the prospective VITamins And Lifestyle (VITAL) study
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Cancer Epidemiol Biomarkers Prev 20:2298-308. 2011
    ..Increasing evidence suggests that nutrients from fruits and vegetables have chemoprotective effects on various cancers including hematologic malignancies, but the effects of nutritional supplements are poorly examined...
  17. pmc Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment
    Roland B Walter
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2 190, Seattle, WA 98109 1024, USA
    J Clin Oncol 29:4417-23. 2011
    ..Eligibility for intensive AML treatment protocols is therefore typically based on age as the implied principal predictor of TRM, although other health- and disease-related factors modulate this age effect...
  18. pmc Cancer risk associated with long-term use of acetaminophen in the prospective VITamins and lifestyle (VITAL) study
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Cancer Epidemiol Biomarkers Prev 20:2637-41. 2011
    ....
  19. pmc Pretargeted radioimmunotherapy for hematologic and other malignancies
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Cancer Biother Radiopharm 25:125-42. 2010
    ..With continued research, PRIT-based treatment strategies promise to become cornerstones to improved outcomes for cancer patients despite their complexities...
  20. pmc High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2 190, Seattle, WA 98109 1024, USA
    J Clin Oncol 28:2831-8. 2010
    ..To evaluate the prognostic significance of the integrin cell adhesion molecule very late antigen-4 (VLA-4) in acute myeloid leukemia (AML)...
  21. ncbi Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 102:1466-73. 2003
    ..Because MK-571 and CSA failed to affect cytotoxicity in a portion of Pgp-positive/MRP-positive AML samples, additional resistance mechanisms are likely important...
  22. ncbi Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2 373, Seattle, WA 98109 1024, USA
    Blood 105:1295-302. 2005
    ....
  23. pmc PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 106:3584-93. 2005
    ....
  24. pmc CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 109:4168-70. 2007
    ..The inverse relationship between CD33 and Pgp suggests a maturation-stage-dependent expression of both proteins, and offers the rationale for using cell differentiation-promoting agents to enhance GO-induced cytotoxicity...
  25. ncbi ITIM-dependent endocytosis of CD33-related Siglecs: role of intracellular domain, tyrosine phosphorylation, and the tyrosine phosphatases, Shp1 and Shp2
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2 373, Seattle, WA 98109 1024, USA
    J Leukoc Biol 83:200-11. 2008
    ..Our studies show that restraint of CD33 internalization through the intracellular domain is relieved partly when the ITIMs are phosphorylated and show that Shp1 and Shp2 can modulate this process...
  26. ncbi Phosphorylated ITIMs enable ubiquitylation of an inhibitory cell surface receptor
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109 1024, USA
    Traffic 9:267-79. 2008
    ....
  27. pmc Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study
    Roland B Walter
    Clinical Research Division and Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Clin Oncol 28:1766-71. 2010
    ..Although the significance of CRp for survival remains unclear, reports of AML trials frequently combine CR with CRp rather than considering CR as a separate entity...
  28. pmc Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 111:4813-6. 2008
    ..These data suggest that further study of this antibody combination for clinical use in AML is warranted...
  29. ncbi The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 103:4276-84. 2004
    ..Since PK11195 is well tolerated in humans as a single agent, its further study as a multifunctional chemosensitizer for anti-AML therapies, including GO-based therapies, is warranted...
  30. pmc Acute severe anaemia in an elderly patient with hereditary sphaerocytosis
    A Imhof
    Department of Medicine, Regionalspital, Langenthal, Switzerland
    Postgrad Med J 79:244, 246. 2003
  31. ncbi Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study
    Alexander Imhof
    Department of Internal Medicine, Medical Clinic B, University Hospital, Zurich, Switzerland
    Clin Infect Dis 36:943-51. 2003
    ..In conclusion, continuous infusion of AmB-d escalated to 2.0 mg/kg/day seems not to cause additional impairment of vital organ functions and to be well tolerated by most patients...
  32. ncbi Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia
    S A Buckley
    Department of Medicine, Division of General Internal Medicine, University of Washington, Seattle, WA, USA
    Bone Marrow Transplant 48:630-41. 2013
    ..Ultimately, controlled clinical studies are needed to define the value of MRD-directed therapies, and patients should be encouraged to enter such trials...
  33. ncbi Safety of lumbar puncture for adults with acute leukemia and restrictive prophylactic platelet transfusion
    Stephan R Vavricka
    Department of Internal Medicine, University Hospital of Zurich, Raemistrasse 100, 8091, Zurich, Switzerland
    Ann Hematol 82:570-3. 2003
    ....
  34. ncbi Expression of the hemoglobin scavenger receptor (CD163/HbSR) as immunophenotypic marker of monocytic lineage in acute myeloid leukemia
    Roland B Walter
    Blood 101:3755-6. 2003
  35. ncbi Functional expression of the CD163 scavenger receptor on acute myeloid leukemia cells of monocytic lineage
    Esther B Bachli
    Department of Medicine, University Hospital of Zurich, CH 8091 Zurich, Switzerland
    J Leukoc Biol 79:312-8. 2006
    ....